Results 81 to 90 of about 35,596 (239)
A Simulation Platform to Examine Heterogeneity Influence on Treatment [PDF]
, 2013 Although a protocol aims to guide treatment management and optimize overall outcomes, the benefits and harms for each individual vary due to heterogeneity. Some protocols integrate clinical and genetic variation to provide treatment recommendation; it is
Chi, Chih-Lin +5 more
core
Allelic Variants in the Warfarin-related Genes VKORC1 and CYP2C9 in a Western Saudi Population [PDF]
, 2023 Amina M. Bagher +4 more
openalex +1 more source
Chemistry &Biodiversity, Volume 23, Issue 1, January 2026.ABSTRACT The aims of this study were to investigate in vitro cytotoxic potential and the effects of daily administration during the inflammatory response induced by sponge implants in mice of the sesquiterpene 9‐deoxymuzigadial (9‐DOM), isolated from Drimys brasiliensis (Winteraceae).
Bruno Antonio Ferreira +7 more
wiley +1 more source
Concentration–QTc Modeling to Support Clinical Development of Fezolinetant
Clinical Pharmacology in Drug Development, Volume 15, Issue 1, January 2026.Abstract Fezolinetant is a non‐hormonal, selective neurokinin‐3 receptor antagonist that blocks neurokinin B activation of kisspeptin/neurokinin B/dynorphin neurons to thereby modulate neuronal activity in the thermoregulatory center. Fezolinetant has been approved in many regions, including North America, Europe, Asia, and Australia for the treatment ...
Jace C. Nielsen +6 more
wiley +1 more source
A Human Mass Balance and Metabolism Study of [14C]‐Ubrogepant in Healthy Male Adults
Clinical Pharmacology in Drug Development, Volume 15, Issue 1, January 2026.Abstract Ubrogepant is a calcitonin gene–related peptide receptor antagonist approved for the acute treatment of migraine with or without aura in adults. The mass balance and metabolism of ubrogepant was evaluated in six healthy male adults administered a single oral dose of [14C]‐ubrogepant 50 mg (∼200 µCi).
Ramesh R. Boinpally +13 more
wiley +1 more source
No exon 4 polymorphism of cytochrome P450 CYP2C9 in Taiwanese [PDF]
, 2003 Jan‐Gowth Chang
openalex +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 89-100, January 2026.This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni +3 more
wiley +1 more source
CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes [PDF]
, 2004 Renate Schmidt +7 more
openalex +1 more source
Cytochrome P450 2C9-CYP2C9 [PDF]
Pharmacogenetics and Genomics, 2010 Derek, Van Booven +6 more
openaire +2 more sources
Mycobacterium avium subspecies paratuberculosis bacteremia in type 1 diabetes mellitus: an infectious trigger? [PDF]
, 2008 Mycobacterium avium subspecies paratuberculosis (MAP) is the established cause of paratuberculosis in ruminants (i.e., Johne disease). The bacterium is shed in the milk of infected cows and survives pasteurization.
Paccagnini, Daniela +2 more
core